Baseline patient characteristics and clinical information
| . | Patients (n = 73) . | IL-6/STAT3_Down (n = 28) . | IL-6/STAT3_Up (n = 26) . | P . |
|---|---|---|---|---|
| Age (median, range), y | 72.9 (32.78-86.7) | 73.1 (48.6-86.7) | 71.05 (34.6-83) | .634 |
| >65 | 58 (79.4%) | |||
| <65 | 15 (20.6%) | |||
| Sex | .747 | |||
| Male | 56 (76.7%) | 21 (75%) | 21 (80.8%) | |
| Female | 17 (23.2%) | 7 (25%) | 5 (19.2%) | |
| Baseline blood counts | ||||
| Hemoglobin, g/dL | 9.1 (3-13.9) | 9.1 (6.2-12.1) | 9.35 (6.9-13.9) | .473 |
| ANC, ×109/L | 1.58 (0.04-17.76) | 1.69 (0.04-16.39) | 1.75 (0.25-17.76) | .489 |
| Platelets, ×109/L | 77.5 (5-490) | 80 (5-481) | 82 (15-301) | .482 |
| Number of completed cycles | .007 | |||
| Median (range) | 7 (2-36) | 15 (6-34) | 6 (6-35) | |
| WHO classification | .624 | |||
| RCMD | 7 (9.5%) | 2 (7.2%) | 4 (15.4%) | |
| RAEB-II | 38 (52%) | 14 (50%) | 9 (34.6%) | |
| CMML-II | 15 (20.5%) | 6 (21.4%) | 7 (26.9%) | |
| AML-MDS | 13 (18%) | 6 (21.4%) | 6 (23.1%) | |
| IPSS | .901 | |||
| Intemediate-1 | 12 (16.4%) | 4 (14.3%) | 4 (15.4%) | |
| Intermediate-2 | 30 (41.1%) | 13 (46.4%) | 12 (46.1%) | |
| High | 26 (35.6%) | 11 (39.3%) | 8 (30.8%) | |
| N/A | 5 (6.9%) | — | 2 (7.7%) | |
| WPSS | .542 | |||
| Intermediate | 1 (1.4%) | — | — | |
| High | 34 (46.6%) | 13 (46.4%) | 11 (42.3%) | |
| Very high | 17 (23.2%) | 9 (32.2%) | 5 (19.2%) | |
| N/A | 21 (28.8%) | 6 (21.4%) | 10 (38.5%) | |
| IPSS-R | .733 | |||
| Intermediate | 5 (6.9%) | 1 (3.6%) | 2 (7.7%) | |
| High | 33 (45.2%) | 16 (57.1%) | 12 (46.1%) | |
| Very high | 28 (38.3%) | 11 (39.3%) | 9 (34.6%) | |
| N/A | 7 (9.6%) | — | 3 (11.6%) | |
| IPSS-R cytogenetic risk | .858 | |||
| Good | 33 (45.2%) | 11 (39.3%) | 12 (46.1%) | |
| Intermediated | 12 (16.4%) | 6 (21.4%) | 5 (19.2%) | |
| Poor | 17 (23.2%) | 9 (32.2%) | 6 (23.1%) | |
| Very poor | 6 (8.3%) | 2 (7.1%) | 1 (3.9%) | |
| N/A | 5 (6.9%) | — | 2 (7.7%) | |
| PB blasts | .213 | |||
| Present | 37 (50.7%) | 16 (57.1%) | 13 (50%) | |
| Absent | 26 (35.6%) | 5 (17.9%) | 10 (28.5%) | |
| N/A | 10 (13.7%) | 7 (25%) | 3 (11.5%) | |
| BM blasts | .074 | |||
| >15% | 35 (48%) | 5 (17.9%) | 11 (42.3%) | |
| ≤15% | 38 (52%) | 23 (82.1%) | 15 (57.7%) | |
| Transfusions ≥4 RBC U/8 wk | .99 | |||
| Yes | 23 (31.5%) | 6 (21.4%) | 6 (23.1%) | |
| No | 50 (68.5%) | 22 (78.6%) | 20 (76.9%) | |
| Best response | .001 | |||
| Complete and partial remission | 24 (31.3%) | 18 (64.3%) | 4 (15.4%) | |
| Hematologic improvement | 7 (10.5%) | 2 (7.1%) | 5 (19.2%) | |
| Stable disease | 17 (25.4%) | 4 (14.3%) | 6 (23.1%) | |
| Failure | 25 (32.8%) | 4 (14.3%) | 11 (42.3%) |
| . | Patients (n = 73) . | IL-6/STAT3_Down (n = 28) . | IL-6/STAT3_Up (n = 26) . | P . |
|---|---|---|---|---|
| Age (median, range), y | 72.9 (32.78-86.7) | 73.1 (48.6-86.7) | 71.05 (34.6-83) | .634 |
| >65 | 58 (79.4%) | |||
| <65 | 15 (20.6%) | |||
| Sex | .747 | |||
| Male | 56 (76.7%) | 21 (75%) | 21 (80.8%) | |
| Female | 17 (23.2%) | 7 (25%) | 5 (19.2%) | |
| Baseline blood counts | ||||
| Hemoglobin, g/dL | 9.1 (3-13.9) | 9.1 (6.2-12.1) | 9.35 (6.9-13.9) | .473 |
| ANC, ×109/L | 1.58 (0.04-17.76) | 1.69 (0.04-16.39) | 1.75 (0.25-17.76) | .489 |
| Platelets, ×109/L | 77.5 (5-490) | 80 (5-481) | 82 (15-301) | .482 |
| Number of completed cycles | .007 | |||
| Median (range) | 7 (2-36) | 15 (6-34) | 6 (6-35) | |
| WHO classification | .624 | |||
| RCMD | 7 (9.5%) | 2 (7.2%) | 4 (15.4%) | |
| RAEB-II | 38 (52%) | 14 (50%) | 9 (34.6%) | |
| CMML-II | 15 (20.5%) | 6 (21.4%) | 7 (26.9%) | |
| AML-MDS | 13 (18%) | 6 (21.4%) | 6 (23.1%) | |
| IPSS | .901 | |||
| Intemediate-1 | 12 (16.4%) | 4 (14.3%) | 4 (15.4%) | |
| Intermediate-2 | 30 (41.1%) | 13 (46.4%) | 12 (46.1%) | |
| High | 26 (35.6%) | 11 (39.3%) | 8 (30.8%) | |
| N/A | 5 (6.9%) | — | 2 (7.7%) | |
| WPSS | .542 | |||
| Intermediate | 1 (1.4%) | — | — | |
| High | 34 (46.6%) | 13 (46.4%) | 11 (42.3%) | |
| Very high | 17 (23.2%) | 9 (32.2%) | 5 (19.2%) | |
| N/A | 21 (28.8%) | 6 (21.4%) | 10 (38.5%) | |
| IPSS-R | .733 | |||
| Intermediate | 5 (6.9%) | 1 (3.6%) | 2 (7.7%) | |
| High | 33 (45.2%) | 16 (57.1%) | 12 (46.1%) | |
| Very high | 28 (38.3%) | 11 (39.3%) | 9 (34.6%) | |
| N/A | 7 (9.6%) | — | 3 (11.6%) | |
| IPSS-R cytogenetic risk | .858 | |||
| Good | 33 (45.2%) | 11 (39.3%) | 12 (46.1%) | |
| Intermediated | 12 (16.4%) | 6 (21.4%) | 5 (19.2%) | |
| Poor | 17 (23.2%) | 9 (32.2%) | 6 (23.1%) | |
| Very poor | 6 (8.3%) | 2 (7.1%) | 1 (3.9%) | |
| N/A | 5 (6.9%) | — | 2 (7.7%) | |
| PB blasts | .213 | |||
| Present | 37 (50.7%) | 16 (57.1%) | 13 (50%) | |
| Absent | 26 (35.6%) | 5 (17.9%) | 10 (28.5%) | |
| N/A | 10 (13.7%) | 7 (25%) | 3 (11.5%) | |
| BM blasts | .074 | |||
| >15% | 35 (48%) | 5 (17.9%) | 11 (42.3%) | |
| ≤15% | 38 (52%) | 23 (82.1%) | 15 (57.7%) | |
| Transfusions ≥4 RBC U/8 wk | .99 | |||
| Yes | 23 (31.5%) | 6 (21.4%) | 6 (23.1%) | |
| No | 50 (68.5%) | 22 (78.6%) | 20 (76.9%) | |
| Best response | .001 | |||
| Complete and partial remission | 24 (31.3%) | 18 (64.3%) | 4 (15.4%) | |
| Hematologic improvement | 7 (10.5%) | 2 (7.1%) | 5 (19.2%) | |
| Stable disease | 17 (25.4%) | 4 (14.3%) | 6 (23.1%) | |
| Failure | 25 (32.8%) | 4 (14.3%) | 11 (42.3%) |
IL-6/STAT3_Down represents IL-6/STAT3 downregulators and IL-6/STAT3_Up represents IL-6/STAT3 upregulators.
ANC, absolute neutrophil count; BM, bone marrow; CMML-II, chronic myelomonocytic leukemia type 2; IPSS-R, Revised International Prognostic Scoring System; N/A, not applicable/not available; PB, peripheral blood; RAEB-II, refractory anemia with excess blasts type 2; RBC, red blood cell; RCMD, refractory cytopenia with multilineage dysplasia; WHO, World Health Organization; WPSS, WHO classification-based prognostic scoring system.